These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38154595)

  • 1. Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?
    Wills A; Mitha A
    Value Health; 2024 Mar; 27(3):340-346. PubMed ID: 38154595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manufacturers' views on outcome-based agreements.
    Barjestehvan Waalwijk van Doorn-Khosrovani S; Timmers L; Pisters-van Roy A; Gijzen J; Blijlevens NMA; Bloemendal H
    J Mark Access Health Policy; 2021; 9(1):1993593. PubMed ID: 34745459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.
    Avşar TS; Elvidge J; Hawksworth C; Kenny J; Németh B; Callenbach M; Ringkvist J; Dawoud D
    Value Health; 2024 Jul; ():. PubMed ID: 39094693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?
    Cheung WY; Cameron C; Mitha A; Wills A
    Support Care Cancer; 2022 Dec; 31(1):5. PubMed ID: 36512133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders.
    Thompson M; Henshall C; Garrison LP; Griffin AD; Coyle D; Long S; Khayat ZA; Anger DL; Yu R
    Clinicoecon Outcomes Res; 2016; 8():427-33. PubMed ID: 27616892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
    Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
    Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
    J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.
    Foroutan N; Tarride JE; Xie F; Jameel B; Mills F; Levine M
    J Popul Ther Clin Pharmacol; 2020 Jan; 27(1):e1-e24. PubMed ID: 31922700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
    Trotta F; Guerrizio MA; Di Filippo A; Cangini A
    JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies.
    Brixner D; Woodward TC; Seifter N; Biskupiak J; Marciniak M; Neumann P; Oderda G
    J Manag Care Spec Pharm; 2019 Feb; 25(2):164-173. PubMed ID: 30698089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
    Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
    J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers.
    Lopata E; Terrone C; Gopalan A; Ladikos N; Richardson T
    J Manag Care Spec Pharm; 2021 Jun; 27(6):706-713. PubMed ID: 33586514
    [No Abstract]   [Full Text] [Related]  

  • 19. Discounts and rebates granted to public payers for medicines in European countries.
    Vogler S; Zimmermann N; Habl C; Piessnegger J; Bucsics A
    South Med Rev; 2012 Jul; 5(1):38-46. PubMed ID: 23093898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.